Terje Pedersen More evidence for the benefits of aggressive lipid-lowering with statins has come from the IDEAL study, which randomised nearly 9000 post-MI patients to either 80 mg of atorvastatin or
Terje Pedersen
More evidence for the benefits of aggressive lipid-lowering with statins has come from the IDEAL study, which randomised nearly 9000 post-MI patients to either 80 mg of atorvastatin or 20/40 mg simvastatin daily.Terje Pedersenfrom Ulleval University Hospital in Norway presented the findings.